New drug aims to control kidney disease in patients not helped by standard care
NCT ID NCT07553494
First seen May 08, 2026 · Last updated May 24, 2026 · Updated 4 times
Summary
This study tests an experimental drug called SLN12140 in 48 adults with IgA nephropathy, a kidney disease that is not well controlled with current treatments. Participants will receive either the drug or a placebo by injection for 36 weeks, and those who may benefit can continue treatment for another year. The goal is to see if the drug can reduce protein in the urine, a sign of kidney damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing University 1st hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.